ImmunityBio, Inc. (IBRX) Q3 2021 Earnings Results

ImmunityBio, Inc. Misses on EPS — Stock Down 1.28%

ImmunityBio's earnings report reflects a challenging quarter with a larger-than-expected loss per share. The stock fell 1.28% in reaction, indicating investor concerns about the company's financial performance. Without revenue figures or updated guidance, investors may be cautious as they await further developments in the company's clinical programs and partnerships.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.22	N/A	-10.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a commitment to advancing their pipeline despite the EPS miss. They remain focused on long-term goals and strategic collaborations.

Management highlighted ongoing efforts in clinical trials and partnerships.

They emphasized the importance of upcoming data releases for future growth.

ImmunityBio, Inc. Misses on EPS — Stock Down 1.28%

Key numbers

Management commentary

ImmunityBio, Inc.

More earnings this week

ImmunityBio, Inc. Misses on EPS — Stock Down 1.28%

Key numbers

Management commentary